Perilla Extract improves gastrointestinal discomfort in a randomized placebo controlled double blind human pilot study

Abstract

BackgroundGastrointestinal (GI) discomfort, e.g. bloating or rumbling, is a common symptom in otherwise healthy adults. Approximately 20% of the population, particularly women suffer from gastrointestinal discomfort and this affects quality of life. Recent studies discovered a link between the body and mind, called the gut-brain axis. Psychosocial factors, such as e.g. daily stress may cause altered gut physiology leading to ileum contractions and consequently gastrointestinal symptoms. In vitro and ex vivo studies clearly showed that a Perilla frutescens extract combines prokinetic, antispasmodic and anti-inflammatory effects. The aim of the intervention was to investigate the effects of the proprietary Perilla extract on GI discomfort in healthy subjects with gastrointestinal discomfort and reduced bowel movements in comparison to a placebo product.MethodsThe pilot study was performed according to a double-blind, randomized, placebo-controlled parallel design. Fifty healthy subjects with gastrointestinal discomfort and reduced bowel movements, 30-70 years, documented their GI symptoms, stool frequency and consistency daily during a 2-week run-in phase and a 4-week intervention phase with Perilla frutescens extract or placebo. GI symptoms were assessed on a 5-point scale daily and average scores over 14 days intervals were calculated.ResultsAll GI symptoms were significantly improved over time by Perilla frutescens extract during the intervention phase (bloating: -0.44 ± 0.56, p = 0.0003; passage of gas: -0.30 ± 0.66, p = 0.0264; GI rumbling: -0.55 ± 0.87, p = 0.0014; feeling of fullness: -0.36 ± 0.72, p = 0.0152; abdominal discomfort: -0.54 ± 0.75, p = 0.004), whereas in the placebo group only abdominal discomfort was significantly improved (-0.31 ± 0.55, p = 0.0345). In the subgroup of women results were strengthened and a subscore out of bloating and abdominal discomfort was significantly improved against placebo (95%CI 0.003 to 0.77; p = 0.048).ConclusionThe demonstrated effects of Perilla frutescens extract to improve GI complaints offer very promising results, taking into consideration the challenging set up of a nutritional human study with healthy subjects and in the area of digestive health, which is known for high placebo effects.Trial registration numberNCT01931930 at ClinicalTrials.gov, Registration date 23rd August 2013.

Perilla frutescens Extracts Protects against Dextran Sulfate Sodium-Induced Murine Colitis: NF-κB, STAT3, and Nrf2 as Putative Targets

“…PE extract (150 mg, twice a day, p.o. ) has been reported to improve gastrointestinal discomfort in a double-blind, randomized, placebo-controlled study ( Buchwald-Werner et al, 2014 ). PE contains many polyphenols and some of them have strong anti-inflammatory and antioxidant effects ( Zhou et al, 2014 ).…”

Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial

“…Assuming alpha equaled to 5% and a power of 80%, the sample size was estimated with a difference in PAC‐SYM of 4.08 units between groups, and a standard deviation (SD) of 6.36 units. The above assumptions were based on prior studies with probiotic and plant extract interventions that used the PAC‐SYM score to assess symptoms. Accounting for premature withdrawal, 100 participants were forecasted for randomization, with 50 participants in each group.…”

A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial

“…Validated ‘quality of life questionnaires’ are also considered to provide supportive evidence for claims on GI discomfort. Therefore, we have made use of previously validated questionnaires in order to investigate the effects on symptoms of GI dysfunction, stool frequency/consistency and constipation-associated quality of life [ 14 , 33 ] (see further below).…”

“…In most instances, it is challenging to show beneficial gut health effects within a target population of healthy individuals [ 14 ]. Therefore, most, if not all trials enrol specific patient groups in gut-health studies.…”